MYCN amplification levels in primary retinoblastoma tumors analyzed by Multiple Ligation-dependent Probe Amplification
Retinoblastoma (Rb) is a childhood tumor of the developing retina where predisposition is caused by pathogenic variants. amplification ( ) has been implicated in around 2% of sporadic unilateral Rb tumors with no detectable variants. We audited data from tumors collected between 1993 and 2019 to det...
Saved in:
Published in | Ophthalmic genetics Vol. 42; no. 5; pp. 604 - 611 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.10.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Retinoblastoma (Rb) is a childhood tumor of the developing retina where predisposition is caused by
pathogenic variants.
amplification (
) has been implicated in around 2% of sporadic unilateral Rb tumors with no detectable
variants. We audited data from tumors collected between 1993 and 2019 to determine if this is the case for patients treated at Barts Health NHS Trust, and how often it occurred alongside
variants.
Screening for
was carried out by Multiple Ligation Probe Analysis of tumor and blood samples collected for
genetic screening. The cohort consisted of 149 tumors, of which 114 had matched blood samples.
10/149 (6.7%) tumors were positive for
in a population containing a disproportionate number of cases negative for
pathogenic variants. Of 65 unbiased tumors collected from 2014 to 2019, 2 (3.1%) had
. All
samples were from sporadic, unilateral patients and 3/10 (30%) had
pathogenic variants.
was not detected in any blood sample. No
tumor had 6p gain which is usually a common alteration in Rbs.
occurs in a small fraction of Rbs and can occur in the presence of pathogenic
variants. However, where it occurs alongside
alterations, the age of onset appears to be later.
has yet to be seen as a heritable change. In sporadic cases with early diagnosis, Rbs with no
pathogenic variant identified should be tested for
. Conversely, tumors with
should still be screened for
pathogenic variants. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1381-6810 1744-5094 |
DOI: | 10.1080/13816810.2021.1923038 |